ANDRX TO FILE SEVEN TO 10 ANDAs FOR CONTROLLED-RELEASE GENERICS
This article was originally published in The Tan Sheet
ANDRX TO FILE SEVEN TO 10 ANDAs FOR CONTROLLED-RELEASE GENERICS "during the second half of 1994 and the first quarter of 1995," the Ft. Lauderdale, Fla.-based company said in a March 23 prospectus for an initial public offering. Andrx has 15 generics under development, eight of which are expected to be licensed in the U.S. to other firms; three are over-the-counter products.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC